ACID PHOSPHATASE

REF 1100005
4 x 10 mL
CONTENTS
ACID PHOSPHATASE
R1. Reagent 1 x 40 mL
TOTAL AND PROSTATIC
R2. Reagent 1 x 20 mL Colorimetric method
R3. Reagent 4 x 10 mL
R4. Reagent 1 x 3 mL
KINETIC
OPTIMIZED
For in vitro diagnostic use only

PRINCIPLE
The method is based on the hydrolysis of -naphtyl phosphate
1,2 Specimens not preserved in this manner are unsuitable for analysis.
at pH 5.0 by acid phosphatase (ACP) to produce -naphtol and ACP activity in preserved serum is stable for 4-5 days at 2-8ºC.
inorganic phosphate. The pentanediol acts as a phosphate
acceptor increasing the reaction sensitivity. INTERFERENCES
The -naphtol reacts with Fast Red TR*, to produce a coloured
complex directly proportional to the activity of the ACP in the  Lipemia (intralipid 1,25 g/L) may affect the results.
sample.  Bilirubin (1,25 g/L) may affect the results.
ACP
-Naphtyl phosphate + H2O -Naphtol + Pi  Hemoglobin may affect the results.
 Other drugs and substances may interfere5-6.
pH 5,0
-Naphtol + Fast Red TR Azo dye MATERIALS REQUIRED
30-37ºC
* Diazotized 2- Amino-5-chlorotoluene  Photometer or spectrophotometer with a thermostatted cell
compartment set at 30/37ºC, capable of reading at 405 nm.
The sample tested in the presence of L-tartrate inhibits the  Stopwatch, strip-chart recorder or printer.
prostatic acid phosphatase of the total ACP activity.
 Cuvettes with 1-cm pathlength.
 Pipettes to measure reagent and samples.
REAGENT COMPOSITION
PROCEDURE
R1 Citrate buffer. Sodium citrate 110 mmol/L, 1,5-pentanediol
220 mmol/L, pH 5.2. 1. Preincubate working reagent, samples and controls to reaction
temperature.
R2 Citrate/Tartrate buffer. Sodium citrate 110 mmol/L, 1,5- 2. Set the photometer to 0 absorbance with distilled water.
pentanediol 220 mmol/L, L-tartrate 110 mmol/L, pH 5.2. 3. For Total acid and/or Non-Prostatic acid tests pipette into
labelled cuvettes:
R3 ACP sustrate. Powder. -Naphtyl phosphate 12.5 mmol/L,
Fast Red TR 1.25 mmol/L, after reconstitution.
TUBES Total Non-Prostatic
R4 Stabilizer. Acetate buffer 5 M/L, pH 5.2.
Working reagent R1 1.0 mL -
STORAGE AND STABILITY Working reagent R2 - 1.0 mL
Sample or control 100 L 100 L
Store at 2-8ºC.
All the kit compounds are stable until the expiry date stated on the 4. Mix gently by inversion. Insert cuvette into the cell holder and
label. Do not use reagents over the expiration date. start stopwatch.
Store the vials tightly closed, protected from light and prevented 5. Incubate for 5 minutes and record initial absorbance reading.
contaminations during the use. 6. Repeat the absorbance readings exactly after 1, 2 and 3 minutes.
Discard If appear signs of deterioration: 7. Calculate the difference between absorbances.
- Presence of particles and turbidity. 8. Calculate the mean of the results to obtain the average change
- Blank absorbance (A) at 405 nm > 0.400 in 1cm cuvette. in absorbance per minute (A/min).

REAGENT PREPARATION CALCULATIONS

Working reagent. Add 10 mL of R1 (total ACP) or 10 mL of R2 A. Total Acid Phosphatase

(non-prostatic ACP) into a vial of R3. Cap and swirl gently until U/L = A/ min x 853
complete solution. Do not shake. The reagent is stable for 10 days
B. Non-Prostatic Acid Phosphatase
at 2-8ºC.
U/L = A/ min x 853
SAMPLES C. Prostatic Acid Phosphatase
Clear, unhemolyzed serum, separated from the clot, immediately. A (U/L) – B (U/L) = Prostatic Acid Phosphatase
Do not use plasma. Oxalates and sodium fluoride inhibit ACP while Samples with A/min exceeding 0.170 at 450 nm should be diluted
heparin and EDTA cause turbidity in the sample. 1:3 with saline and assayed again. Multiply the results by 3.
To stabilize the enzyme after separation of the serum from the clot,
If results are to be expressed as SI units apply:
add 50 L of R4 to 1 mL of sample.
U/L x 16.67 = kat/L

QUALITY SYSTEM CERTIFIED LINEAR CHEMICALS, S.L.U. Joaquim Costa 18 2ª planta. 08390 Montgat (Barcelona) SPAIN
ISO 9001 ISO 13485 Telf. (+34) 934 694 990; E-mail: [email protected] ; website: www.linear.es NIF-VAT:B60485687
 REFERENCE VALUES 4 NOTES
Serum
1. This method may be used with different instruments. Any
application to an instrument should be validated to demonstrate
Reaction temperature 37ºC 30ºC
that results meets the performance characteristics of the method.
It is recommended to validate periodically the instrument. Contact
Total ACP, up to 6.6 U/L (110 nkat/L) 7.0 U/L (278 nkat/L) to the distributor for any question on the application method.

Prostatic ACP, up to 3.5 U/L (108 nkat/L) 2.6 U/L (43 nkat/L) 2. Clinical diagnosis should not be made on findings of a single test
result, but should integrate both clinical and laboratory data.

It is recommended that each laboratory establishes its own

reference range. REFERENCES

QUALITY CONTROL 1. Hillmann, G.V. Clin. Chem. Biochem. 9 : 273 (1971).

2. Fabiny-Byrd, DL y Ertinghausen. Clin.Chem 13:841 (1972).
To ensure adequate quality control (QC), each run should include a 3. Young, D.S., Pestaner, L.D. and Gibberman, V. Clin Chem.
set of controls (normal and abnormal) with assayed values handled 21, Vol. 5, 10-432D (1975).
as unknowns. 4. Junge, W. et al. Pecs, Hongrie: 3rd Alpe-Adria Congress on
Clinical Chemistry and Laboratory Medicine, 7-9 Septembre
REF 1980005 HUMAN MULTISERA NORMAL 1994.
Borderline level of ACP. Assayed. 5. Young DS. Effects of drugs on clinical laboratory tests, 4th
ed. AACC Press, 1995.
REF 1985005 HUMAN MULTISERA ABNORMAL 6. Tietz. N.W. Textbook of Clinical Chemistry, 2th Edition. Burtis
Elevated level of ACP. Assayed. CA, Ashwood ER. W.B. Saunders Co. 1994.

If the values are found outside of the defined range, check the
instrument, reagents and procedure.
Each laboratory should establish its own Quality Control scheme
and corrective actions if controls do not meet the acceptable
tolerances.

CLINICAL SIGNIFICANCE

Determination of acid phosphatase activity in serum is directed

toward the prostatic enzyme with the intent of detecting carcinoma
of the prostate.
Elevations of the activity are found in the sera of about 60% of men
with prostatic cancer with metastases.
Slight elevations in total enzyme are observed in cases of
thromboembolic phenomena, multiple myeloma, thrombocytopenia
and liver disease.
Moderate elevations in total acid phosphatase activity often occur in
Paget´s disease, in hyperparathyroidism with skeletal involvement,
and in the presence of malignant invasion of the bones by cancers.
The serum activity in these cases is not inhibited by tartrate. The
only non-bone condition in which elevated activities of tartrate-
resistant osteoclast-type acid phosphatase are found in serum is
Gaucher´s disease.

ANALYTICAL PERFORMANCE

- Detection Limit : 2.74 U/L

- Linearity : Up to 150 U/L
- Precision:
U/L Within-run Between-run
Mean 28.2 63.6 28.2 63.6
SD 0.40 0.89 1.41 2.85
CV% 1.43 1.41 4.98 4.48
N 10 10 10 10

- Sensitivity : 1,3 mA/min/U/L Acid phosphatase.

- Correlation: This assay (y) was compared with a similar commercial
method (x). The results were:
N = 50 r = 0.987 y = 1.078 x – 2.166
The analytical performances have been generated using on
automatic instrument. Results may vary depending on the
instrument. B1100-3/0901
R1.ing

QUALITY SYSTEM CERTIFIED LINEAR CHEMICALS, S.L.U. Joaquim Costa 18 2ª planta. 08390 Montgat (Barcelona) SPAIN
ISO 9001 ISO 13485 Telf. (+34) 934 694 990; E-mail: [email protected] ; website: www.linear.es NIF-VAT:B60485687